Xconomy - San Francisco gives an update on Jenerex's progress with its oncolytic virus technology targetting liver cancer. The company is seeing good results so far with its JX-594 vaccine directed to patients with hepatocellular carcinoma. So far the company has only been able to look at 26 patients and needs 4 more to complete this small trial.
Jennerex is trying to compare treatment with JX-594 to the current standard of care with Bayer/Onyx Pharmaceuticals Nexavar. They need more patients and need randomized survival data before any conclusions can be definitively drawn.
Based on the limited 26 patient sample, it appears the low dose course with JX-594 is comparable to Nexavar and the high-dose course is performing better using median survival time as a measure (not complete data set yet for statistical significance - watch out in oncology for this!).
Nevertheless, Jennerex's results appear to be positive enough for now to draw more investor interest, especially since Amgen recently acquired another oncolytic virus property in its deal with BioVex. Let's wait for Jennerex next round of larger trial data they hope to complete by the end of 2012.
Posted by Bruce Lehr Feb 19th 2011.